Traws Pharma, Inc. (TRAW) Form 8-K — Oct 23, 2026
Traws Pharma entered into a $50 million common stock purchase agreement with Roth Principal Investments on October 23, 2026, giving the company the right, but not the obligation, to sell newly issued shares over a 36-month term following effectiveness of a resale registration statement. Purchases are priced at 94.0% of VWAP (a 6% discount), capped per-purchase by share and volume limits, and subject to a Nasdaq Exchange Cap of 3,072,118 shares (19.99% of shares outstanding) unless shareholder approval is obtained or pricing exceeds the $0.3663 Base Price. Roth is limited to 4.99% beneficial ownership.
Key figures
- Deal Value Usd
- 50000000
- Shares Outstanding
- 3,072,118 shares equal 19.99% of shares outstanding immediately prior to the agreement (Exchange Cap)
- Qi Uw fee
- $50,000
- Shares reserved
- 60000000
- Threshold price
- $0.10
- Nasdaq minimum price
- $0.3663
- Commitment term months
- 36
- Purchase discount to vwap
- 6.0%
- Beneficial ownership limit
- 4.99%
- Non affiliate market value
- $9.261 million
- Investor legal reimbursement
- $100,000
- Quarterly legal reimbursement cap
- $7,500
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.